



May 6, 2008

Chairman Frank Pallone  
Committee on Energy and Commerce  
Subcommittee on Health  
316 Ford House Office Building  
Washington, DC 20515

Ranking Member Nathan Deal  
Committee on Energy and Commerce  
Subcommittee on Health  
2322-A Rayburn House Office Building  
Washington, DC 20515

Dear Chairman Pallone and Ranking Member Deal,

Thank you very much for the opportunity to comment on the follow-on biologics issue. This is of critical importance to our industry and, I believe, to the nation as a whole as we look to provide access to important and innovative medicines to those who need them.

I serve on the Board of BIO and am also the incoming Chair of the Emerging Companies Section there. I have therefore been very involved with BIO in the development of BIO's position on this issue and support the comments that BIO has provided to you. For reference, I am attaching here the BIO comments.

GlycoMimetics is an early stage biotechnology company planning to enter clinical trials this year. Our lead drug candidate will be tested initially in sickle cell disease, and it has the potential to be used in other conditions as well, including certain types of blood cancer.

Thank you for your attention to the very important issue of follow-on biologics.

Sincerely,

A handwritten signature in blue ink, appearing to read "Rachel King", is written over the typed name.

Rachel K. King  
Chief Executive Officer